



Daniel M. Silver  
Partner  
T. 302-984-6331  
F. 302-691-1260  
dsilver@mccarter.com

McCarter & English, LLP  
Renaissance Centre  
405 N. King Street, 8th Floor  
Wilmington, DE 19801-3717  
www.mccarter.com

April 16, 2020

**VIA CM/ECF**

The Honorable Colm F. Connolly  
United States District Court for the District of Delaware  
J. Caleb Boggs Federal Building  
844 North King Street, Room 3124  
Wilmington, Delaware 19801-3555

**Re: Genentech, Inc. v. Amgen, Inc., C.A. No. 18-924-CFC-SRF (D. Del.)**

Dear Judge Connolly:

Further to my April 2, 2020 letter (D.I. 543), I write to provide the parties' availability for a rescheduled trial in this matter. Subject to Your Honor's availability, the following dates for trial would work for both parties:

February 22, 2021 - March 15, 2021  
July 12, 2021 - December 17, 2021

Genentech believes that trial in this matter could be limited to 5 days, which may provide additional availability to reschedule this trial. Amgen believes that at least 7 days will be necessary to try the three dosing patents and sparging patent, noting particularly that the Court has indicated that infringement, invalidity, damages, and willful infringement would be tried to a jury within this timeframe. In addition, a bench trial following the jury trial may be necessary to address equitable defenses and injunction issues.

To the extent necessary, the parties' Delaware counsel are available to call Chambers to discuss scheduling with Your Honor's civil case manager.

Counsel are available should the Court have any questions.

Respectfully submitted,

*/s/ Daniel M. Silver*

Daniel M. Silver (#4758)

cc: All counsel of record (via CM/ECF)